Literature DB >> 18766334

Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects.

Rui Liu1, Audrey May Yi Tang, Yen Ling Tan, Lie Michael George Limenta, Edmund Jon Deoon Lee.   

Abstract

OBJECTIVES: The aims of this study were to characterize the population frequency of PEPT2 (SLC15A2) polymorphic variants in three Asian ethnic populations, namely Chinese, Malay and Asian Indian, and to investigate the associations of ethnicity (Chinese vs. Asian Indian), PEPT2 haplotype and cephalexin pharmacokinetics in healthy Asian subjects.
METHODS: PEPT2 polymorphisms were screened from a cohort of 96 Chinese, 96 Malay and 96 Asian Indian subjects. Cephalexin (1000 mg, orally) pharmacokinetics was characterized in an additional 15 Chinese and 15 Asian Indian healthy subjects. These 30 subjects were subsequently genotyped for their PEPT2 polymorphisms.
RESULTS: In total, ten common single nucleotide polymorphisms (SNPs) were detected in the three populations, forming two PEPT2 haplotypes. There were significant ethnic differences in PEPT2 haplotype distribution: the frequencies of the *1 and *2 alleles were 0.307 and 0.693 in the Chinese population, 0.495 and 0.505 in the Malay population and 0.729 and 0.271 in Asian Indian population, respectively. The C (max) of cephalexin was significantly lower in the Chinese (29.80 +/- 4.09 microg ml(-1)) population than in the Asian Indian one (33.29 +/- 4.97 microg ml(-1); P = 0.045). This difference could be explained by the higher average body weight of the Chinese population. There was no other significant difference in cephalexin pharmacokinetics between either ethnic or PEPT2 genotype groups.
CONCLUSION: PEPT2 polymorphism distributions differ significantly between Chinese, Malay and Asian Indian populations. However, cephalexin pharmacokinetics is not meaningfully different between Chinese and Asian Indians. The association between the PEPT2 haplotype and cephalexin pharmacokinetics could not be confirmed, and future studies under better controlled conditions are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766334     DOI: 10.1007/s00228-008-0488-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

Review 1.  Mammalian peptide transporters as targets for drug delivery.

Authors:  Isabel Rubio-Aliaga; Hannelore Daniel
Journal:  Trends Pharmacol Sci       Date:  2002-09       Impact factor: 14.819

2.  Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

Authors:  C Padoin; M Tod; G Perret; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin.

Authors:  A I Hartstein; K E Patrick; S R Jones; M J Miller; R E Bryant
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

4.  Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.

Authors:  T Terada; H Saito; M Mukai; K Inui
Journal:  Am J Physiol       Date:  1997-11

5.  Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.

Authors:  J B Lecaillon; J L Hirtz; J P Schoeller; G Humbert; W Vischer
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses.

Authors:  R H Barbhaiya
Journal:  Biopharm Drug Dispos       Date:  1996-05       Impact factor: 1.627

7.  Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A.

Authors:  F Pelloquin; J P Lamelin; G M Lenoir
Journal:  In Vitro Cell Dev Biol       Date:  1986-12

8.  A naturally occurring -263G/C variant of the human AA-NAT gene and overnight melatonin production.

Authors:  Grace Wang Ying; Caroline Guat Lay Lee; Edmund Jon Deoon Lee
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

9.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

Authors:  M E Ganapathy; W Huang; H Wang; V Ganapathy; F H Leibach
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

10.  Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions.

Authors:  Julia Pinsonneault; Carsten Uhd Nielsen; Wolfgang Sadée
Journal:  J Pharmacol Exp Ther       Date:  2004-07-28       Impact factor: 4.030

View more
  8 in total

1.  Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Authors:  Xiaomei Chen; Richard F Keep; Yan Liang; Hao-Jie Zhu; Margareta Hammarlund-Udenaes; Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2017-02-10       Impact factor: 5.858

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

3.  A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease.

Authors:  Dimitri Tchernitchko; Quentin Tavernier; Jérôme Lamoril; Caroline Schmitt; Neila Talbi; Said Lyoumi; Anne-Marie Robreau; Zoubida Karim; Laurent Gouya; Eric Thervet; Alexandre Karras; Hervé Puy; Nicolas Pallet
Journal:  J Am Soc Nephrol       Date:  2016-12-28       Impact factor: 10.121

Review 4.  Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications.

Authors:  David E Smith; Benjamin Clémençon; Matthias A Hediger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

5.  The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.

Authors:  Hannah Yejin Kim; Gareth J Veal; Fanfan Zhou; Alan V Boddy
Journal:  Eur J Clin Pharmacol       Date:  2018-08-30       Impact factor: 2.953

6.  Polymorphisms of delta-aminolevulinic acid dehydratase (ALAD) and peptide transporter 2 (PEPT2) genes in children with low-level lead exposure.

Authors:  Christina Sobin; Marisela Gutierrez; Heather Alterio
Journal:  Neurotoxicology       Date:  2009-08-31       Impact factor: 4.294

7.  Delta-Aminolevulinic Acid Dehydratase, Low Blood Lead Levels, Social Factors, and Intellectual Function in an Afro-Brazilian Children Community.

Authors:  Homegnon A F Bah; Ana Laura S Dos Anjos; Erival A Gomes-Júnior; Matheus J Bandeira; Chrissie F de Carvalho; Nathália R Dos Santos; Victor O Martinez; Elisângela V Adorno; José A Menezes-Filho
Journal:  Biol Trace Elem Res       Date:  2021-03-16       Impact factor: 3.738

8.  Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.

Authors:  A E Muller; N Punt; M Engelhardt; A H Schmitt-Hoffmann; J W Mouton
Journal:  Clin Pharmacol Drug Dev       Date:  2018-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.